Company & Sponsor Intelligence
UCB Japan Co. Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed4
Countries2
Therapeutic footprint
epilepsy
Indexed studies
NCT00367432A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures
epilepsy · JapanPHASE3
epilepsy · JapanPHASE3
NCT02192814Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
epilepsy · JapanPHASE3
epilepsy · JapanPHASE3
NCT01228747A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
epilepsy · ChinaPHASE3
epilepsy · ChinaPHASE3
NCT01292837A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures
epilepsy · JapanPHASE3
epilepsy · JapanPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →